Explore

Trendline Trendline
Inhibrx Reports First Quarter 2026 Financial Results Highlighting Clinical Progress

Inhibrx Reports First Quarter 2026 Financial Results Highlighting Clinical Progress

Inhibrx Reports First Quarter 2026 Financial Results Highlighting Clinical Progress
Trendline Trendline
Inhibrx Biosciences Reports Financial Results Amid Ongoing Clinical Trials

Inhibrx Biosciences Reports Financial Results Amid Ongoing Clinical Trials

Inhibrx Biosciences Reports Financial Results Amid Ongoing Clinical Trials
Trendline Trendline
Spruce Biosciences Reports Q1 2026 Financial Results and Corporate Updates

Spruce Biosciences Reports Q1 2026 Financial Results and Corporate Updates

Spruce Biosciences Reports Q1 2026 Financial Results and Corporate Updates
Trendline Trendline
Spruce Biosciences Reports Q1 2026 Financial Results and Strategic Developments

Spruce Biosciences Reports Q1 2026 Financial Results and Strategic Developments

Spruce Biosciences Reports Q1 2026 Financial Results and Strategic Developments
Trendline Trendline
Savara Reports Increased Losses in Q1 2026 Amid Regulatory Milestones for MOLBREEVI

Savara Reports Increased Losses in Q1 2026 Amid Regulatory Milestones for MOLBREEVI

Savara Reports Increased Losses in Q1 2026 Amid Regulatory Milestones for MOLBREEVI
Trendline Trendline
Longeveron Reports Q1 2026 Financial Results and Strategic Developments in Stem Cell Therapy

Longeveron Reports Q1 2026 Financial Results and Strategic Developments in Stem Cell Therapy

Longeveron Reports Q1 2026 Financial Results and Strategic Developments in Stem Cell Therapy
Trendline Trendline
Immunome Submits NDA for Varegacestat and Reports Financial Results

Immunome Submits NDA for Varegacestat and Reports Financial Results

Immunome Submits NDA for Varegacestat and Reports Financial Results
Trendline Trendline
Spruce Biosciences Strengthens Financial Position Ahead of Potential U.S. Launch of TA-ERT

Spruce Biosciences Strengthens Financial Position Ahead of Potential U.S. Launch of TA-ERT

Spruce Biosciences Strengthens Financial Position Ahead of Potential U.S. Launch of TA-ERT
Trendline Trendline
Innate Pharma Reports Q1 2026 Business Update and Financial Results

Innate Pharma Reports Q1 2026 Business Update and Financial Results

Innate Pharma Reports Q1 2026 Business Update and Financial Results
Trendline Trendline
INOVIO Announces First Quarter 2026 Financial Results and Advances in DNA Medicine Development

INOVIO Announces First Quarter 2026 Financial Results and Advances in DNA Medicine Development

INOVIO Announces First Quarter 2026 Financial Results and Advances in DNA Medicine Development
Trendline Trendline
Adagio Medical Reports Q1 2026 Financial Results and Clinical Progress

Adagio Medical Reports Q1 2026 Financial Results and Clinical Progress

Adagio Medical Reports Q1 2026 Financial Results and Clinical Progress
Trendline Trendline
Curis Reports First Quarter 2026 Financial Results Amid Ongoing Clinical Trials

Curis Reports First Quarter 2026 Financial Results Amid Ongoing Clinical Trials

Curis Reports First Quarter 2026 Financial Results Amid Ongoing Clinical Trials